FDA Grants Interchangeable Designation to Yuflyma (adalimumab-aaty), Celltrion's Biosimilar to Humira (adalimumab)
INCHEON, South Korea, April 14, 2025 /-- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). Yuflyma is an FDA-approved...
INCHEON, South Korea, April 14, 2025 /-- Celltrion, Inc. today announced that the U.S. Food and Drug Administration (FDA) has designated Yuflyma (adalimumab-aaty), as an interchangeable biosimilar to Humira (adalimumab). Yuflyma is an FDA-approved...
